IQVIA Holdings Inc. (NYSE:IQV) Short Interest Down 6.9% in November

IQVIA Holdings Inc. (NYSE:IQV) was the target of a large decline in short interest in November. As of November 30th, there was short interest totalling 3,110,000 shares, a decline of 6.9% from the November 15th total of 3,340,000 shares. Approximately 1.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,510,000 shares, the short-interest ratio is presently 2.1 days.

Hedge Funds Weigh In On IQVIA

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Simplify Asset Management Inc. boosted its stake in IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after acquiring an additional 3,894 shares during the last quarter. Versor Investments LP bought a new position in shares of IQVIA during the third quarter worth about $1,328,000. CIBC Asset Management Inc grew its stake in IQVIA by 3.3% in the third quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock worth $62,501,000 after purchasing an additional 8,490 shares in the last quarter. Sequoia Financial Advisors LLC increased its holdings in IQVIA by 17.5% in the third quarter. Sequoia Financial Advisors LLC now owns 75,054 shares of the medical research company’s stock valued at $17,785,000 after buying an additional 11,170 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its stake in IQVIA by 3.9% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,023,264 shares of the medical research company’s stock worth $242,483,000 after purchasing an additional 38,307 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Down 0.1 %

Shares of IQV traded down $0.15 during mid-day trading on Tuesday, reaching $196.94. 264,194 shares of the stock traded hands, compared to its average volume of 1,184,725. The firm has a market cap of $35.74 billion, a price-to-earnings ratio of 25.86, a P/E/G ratio of 2.05 and a beta of 1.49. The stock has a fifty day simple moving average of $211.68 and a 200 day simple moving average of $224.03. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA has a 12-month low of $187.62 and a 12-month high of $261.73.

Analysts Set New Price Targets

A number of equities analysts have issued reports on IQV shares. BTIG Research cut their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Redburn Atlantic started coverage on IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 target price on the stock. Deutsche Bank Aktiengesellschaft cut their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Truist Financial reduced their target price on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Finally, Morgan Stanley cut their price objective on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $256.19.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.